{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:13:33Z","timestamp":1760645613026},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T00:00:00Z","timestamp":1219276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00198-008-0717-9","type":"journal-article","created":{"date-parts":[[2008,8,20]],"date-time":"2008-08-20T15:20:20Z","timestamp":1219245620000},"page":"647-652","source":"Crossref","is-referenced-by-count":12,"title":["Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra"],"prefix":"10.1007","volume":"20","author":[{"given":"T.","family":"Diab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. B.","family":"Burr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,21]]},"reference":[{"key":"717_CR1","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1172\/JCI111096","volume":"72","author":"AM Parfitt","year":"1983","unstructured":"Parfitt AM, Mathews CH, Villanueva AR et al (1983) Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 72:1396\u20131409","journal-title":"J Clin Invest"},{"key":"717_CR2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJM199502023320506","volume":"332","author":"SC Manolagas","year":"1995","unstructured":"Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305\u2013311","journal-title":"N Engl J Med"},{"key":"717_CR3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u201368 Jan","journal-title":"N Engl J Med"},{"issue":"4 Suppl 1","key":"717_CR4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2005.12.017","volume":"119","author":"M Gass","year":"2006","unstructured":"Gass M, Dawson-Hughes B (2006) Preventing osteoporosis-related fractures: an overview. Am J Med 119(4 Suppl 1):S3\u2013S11","journal-title":"Am J Med"},{"key":"717_CR5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00198-006-0286-8","volume":"18","author":"K Henriksen","year":"2007","unstructured":"Henriksen K, Tanko LB, Qvist P et al (2007) Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18:681\u2013685","journal-title":"Osteoporos Int"},{"key":"717_CR6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"717_CR7","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"717_CR8","first-page":"2731","volume":"61","author":"SL Greenspan","year":"2000","unstructured":"Greenspan SL, Harris ST, Bone H et al (2000) Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician 61:2731\u20132736","journal-title":"Am Fam Physician"},{"key":"717_CR9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"12","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP et al (2004) Alendronate Phase III Osteoporosis Treatment Study Group. Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 12:1189\u20131199","journal-title":"N Engl J Med"},{"key":"717_CR10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00198-004-1725-z","volume":"16","author":"SE Papapoulos","year":"2005","unstructured":"Papapoulos SE, Quandt SA, Liberman UA et al (2005) Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 16:468\u2013474","journal-title":"Osteoporos Int"},{"key":"717_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","volume":"20","author":"CJ Rosen","year":"2005","unstructured":"Rosen CJ, Hochberg MC, Bonnick SL et al (2005) Treatment with once-weekly alendronate 70\u00a0mg compared with once-weekly risedronate 35\u00a0mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141\u201351","journal-title":"J Bone Miner Res"},{"key":"717_CR12","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","volume":"11","author":"P Garnero","year":"1996","unstructured":"Garnero P, Hausherr E, Chapuy MC et al (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531\u20131538","journal-title":"J Bone Miner Res"},{"key":"717_CR13","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1359\/jbmr.1997.12.7.1083","volume":"12","author":"LJ Melton 3rd","year":"1997","unstructured":"Melton LJ 3rd, Khosla S, Atkinson EJ et al (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083\u20131091","journal-title":"J Bone Miner Res"},{"key":"717_CR14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","volume":"19","author":"S Sarkar","year":"2004","unstructured":"Sarkar S, Reginster JY, Crans GG et al (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394\u2013401","journal-title":"J Bone Miner Res"},{"key":"717_CR15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","volume":"19","author":"DC Bauer","year":"2004","unstructured":"Bauer DC, Black DM, Garnero P et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250\u20131258","journal-title":"J Bone Miner Res"},{"issue":"3 Suppl","key":"717_CR16","doi-asserted-by":"crossref","first-page":"197S","DOI":"10.1016\/8756-3282(95)00502-1","volume":"18","author":"BL Riggs","year":"1996","unstructured":"Riggs BL, Melton LJ 3rd, O\u2019Fallon WM (1996) Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18(3 Suppl):197S\u2013201S","journal-title":"Bone"},{"key":"717_CR17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.2002.17.1.11","volume":"17","author":"BL Riggs","year":"2002","unstructured":"Riggs BL, Melton LJ 3rd (2002) Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:11\u201314","journal-title":"J Bone Miner Res"},{"key":"717_CR18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bone.2007.03.019","volume":"41","author":"MP Akhter","year":"2007","unstructured":"Akhter MP, Lappe JM, Davies KM et al (2007) Transmenopausal changes in the trabecular bone structure. Bone 41:111\u2013116","journal-title":"Bone"},{"key":"717_CR19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/er.2006-0029","volume":"28","author":"P Chavassieux","year":"2007","unstructured":"Chavassieux P, Seeman E, Delmas PD (2007) Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev 28:151\u2013164","journal-title":"Endocr Rev"},{"key":"717_CR20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bone.2006.01.161","volume":"39","author":"B Borah","year":"2006","unstructured":"Borah B, Dufresne TE, Ritman EL et al (2006) Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39:345\u2013352","journal-title":"Bone"},{"key":"717_CR21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/8756-3282(95)00120-3","volume":"16","author":"MR Forwood","year":"1995","unstructured":"Forwood MR, Burr DB, Takano Y et al (1995) Risedronate treatment does not increase microdamage in the canine femoral neck. Bone 16:643\u2013650","journal-title":"Bone"},{"key":"717_CR22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00223-005-1295-x","volume":"77","author":"T Mashiba","year":"2005","unstructured":"Mashiba T, Hui S, Turner CH et al (2005) Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif Tissue Int 77:180\u2013185","journal-title":"Calcif Tissue Int"},{"key":"717_CR23","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1359\/jbmr.070720","volume":"22","author":"MR Allen","year":"2007","unstructured":"Allen MR, Burr DB (2007) Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22:1759\u20131765","journal-title":"J Bone Miner Res"},{"key":"717_CR24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bone.2006.04.028","volume":"39","author":"MR Allen","year":"2006","unstructured":"Allen MR, Iwata K, Phipps R et al (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872\u2013879","journal-title":"Bone"},{"key":"717_CR25","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/jbmr.5650051010","volume":"5","author":"J Foldes","year":"1990","unstructured":"Foldes J, Shih MS, Parfitt AM (1990) Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J Bone Miner Res 5:1063\u20131067","journal-title":"J Bone Miner Res"},{"key":"717_CR26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","volume":"2","author":"AM Parfitt","year":"1987","unstructured":"Parfitt AM, Drezner MK, Glorieux FH (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595\u2013610","journal-title":"J Bone Miner Res"},{"key":"717_CR27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bone.2007.06.010","volume":"41","author":"E Seeman","year":"2007","unstructured":"Seeman E (2007) Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 41:308\u2013317","journal-title":"Bone"},{"key":"717_CR28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s002239900713","volume":"65","author":"S Gonnelli","year":"1999","unstructured":"Gonnelli S, Cepollaro C, Pondrelli C et al (1999) Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 65:359\u2013364","journal-title":"Calcif Tissue Int"},{"key":"717_CR29","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0002-9343(96)00282-3","volume":"101","author":"JR Tucci","year":"1996","unstructured":"Tucci JR, Tonino RP, Emkey RD et al (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488\u2013501","journal-title":"Am J Med"},{"key":"717_CR30","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS et al (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294\u20131301","journal-title":"J Clin Endocrinol Metab"},{"key":"717_CR31","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","volume":"100","author":"PM Chavassieux","year":"1997","unstructured":"Chavassieux PM, Arlot ME, Reda C et al (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475\u20131480","journal-title":"J Clin Invest"},{"key":"717_CR32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-003-1530-0","volume":"15","author":"RR Recker","year":"2004","unstructured":"Recker RR, Weinstein RS, Chesnut CH 3rd et al (2004) Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 15:231\u2013237","journal-title":"Osteoporos Int"},{"key":"717_CR33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","volume":"31","author":"EF Eriksen","year":"2002","unstructured":"Eriksen EF, Melsen F, Sod E et al (2002) Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620\u2013625","journal-title":"Bone"},{"key":"717_CR34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","volume":"23","author":"RR Recker","year":"2008","unstructured":"Recker RR, Delmas PD, Halse J et al (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6\u201316","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-008-0717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-008-0717-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-008-0717-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:00:58Z","timestamp":1558638058000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-008-0717-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,21]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1007\/s00198-008-0717-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,21]]}}}